Clinical trials: HIV-1
HIV Infections
An Expanded Access Open Label Protocol of Remune (HIV-1 Immunogen) in HIV-1-Infected Adults With CD4 Count 550 Cells /Ml and Greater.
To provide an alternative therapy to HIV-infected patients for whom there is no comparable or satisfactory alternative drug or therapy available.
- Trial name
- NCT00002173
- Testing
- HIV-1 Immunogen
- Where
- United States
- Sponsor
- The Immune Response Corporation
Infection, Human Immunodeficiency Virus
A Study to Assess Dolutegravir in HIV-infected Subjects With Treatment Failure on an Integrase Inhibitor Containing Regimen.
The purpose of this trial is to assess the antiviral activity and safety of a dolutegravir (DTG) containing regimen in HIV-1 infected, antiretroviral therapy (ART)-experienced adults with current or historical failure on an…
- Trial name
- VIKING-3 (NCT01328041)
- Testing
- dolutegravir
- Where
- 89 sites in United States, Belgium and 5 more
- Volunteers
- 183 people
- Sponsor
- ViiV Healthcare
HIV-1
Multiple Dose BE Study With Nevirapine 400mg PR Tablets
The objective of this steady state pivotal study is to compare the rate and extent of absorption and to evaluate Bioequivalence of test drug compared to the approved reference product in HIV infected individuals
- Trial name
- NCT02202005
- Testing
- Nevirapine, Viramune®
- Where
- United Kingdom
- Volunteers
- 46 people
- Sponsor
- Ratiopharm GmbH
HIV Infections
A Study of Ritonavir-Boosted Invirase (Saquinavir) in Treatment-Naïve HIV-1 Infected Patients
This open-label study will evaluate the safety, pharmacokinetics and antiviral activity of a modified Invirase (saquinavir)/ritonavir regimen in treatment-naïve HIV-1 infected patients.
- Trial name
- NCT01638650
- Testing
- Nucleoside Reverse Transcriptase Inhibitor (NRTIs), ritonavir, saquinavir [Invirase]
- Where
- United Kingdom
- Volunteers
- 23 people
- Sponsor
- Hoffmann-La Roche
HIV Infections
Dolutegravir/Rilpivirine, Antiretroviral Efficacy Study Using Real-world Data in Subjects With Human Immunodeficiency Virus (HIV)-1
This was a prospective, non-interventional, single-arm, multi-center study aimed at gathering real-world data on JULUCA use in routine clinical care in Germany, to supplement clinical trial data to further improve/optimize care…
- Trial name
- JUNGLE (NCT03518060)
- Testing
- JULUCA
- Where
- 23 sites in Germany
- Volunteers
- 209 people
- Sponsor
- ViiV Healthcare
HIV Infection
Safety Of VIRACEPT® 625mg Administered To HIV-Infected Women During Pregnancy
This study is an evaluation of the safety of 625 mg formulation when administered to HIV-infected pregnant women from their second trimester through six weeks postpartum.
- Trial name
- NCT00246610
- Testing
- Nelfinavir mesylate, 625 mg
- Where
- 6 sites in United States, Canada
- Volunteers
- 16 people
- Sponsor
- Pfizer
AIDS
Efficacy and Safety of GSK Biologicals HIV Vaccine in Antiretroviral Therapy (ART)-naïve HIV-1 Infected Persons
This study is designed to determine whether administration of the GSK Biologicals HIV vaccine 732462 can lead to a reduction in viral load, and impact on the course of human immunodeficiency virus type 1 (HIV-1) infection.
- Trial name
- NCT01218113
- Testing
- GSK Biologicals HIV Vaccine 732462
- Where
- 42 sites in United States, France and 2 more
- Volunteers
- 191 people
- Sponsor
- GlaxoSmithKline
HIV-1 Infection
Study to Evaluate the Safety and Efficacy of Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Abacavir/Dolutegravir/Lamivudine in Human Immunodeficiency Virus-1 (HIV-1) Infected, Antiretroviral Treatment-Naive Adults
The primary objective of this study is to evaluate the efficacy of a fixed dose combination (FDC) containing bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) versus a FDC containing abacavir/dolutegravir/lamivudine…
- Trial name
- NCT02607930
- Testing
- ABC/DTG/3TC, B/F/TAF
- Where
- 121 sites in United States, Belgium and 8 more
- Volunteers
- 631 people
- Sponsor
- Gilead Sciences
HIV Infections
Safety and Effectiveness of Giving Combinations of Three or Four Anti-HIV Drugs to HIV-Infected Patients
The purpose of this study is to see if it is safe and effective to give combinations of three or four anti-HIV drugs to HIV-infected patients.
- Trial name
- NCT00002211
- Testing
- Nelfinavir mesylate, Delavirdine mesylate, Stavudine
- Where
- United States
- Volunteers
- 160 people
- Sponsor
- Pharmacia and Upjohn
HIV Infections
A Phase 4 Cross-Sectional Study of Bone Mineral Density in HIV-1 Infected Subjects
A Phase 4 study is to characterize the profile of low bone mineral density (BMD) in ≥ 50 year old male subjects and post-menopausal female subjects on any tenofovir disoproxil fumarate (TDF)-based regimen
- Trial name
- NCT01850212
- Where
- 73 sites in Austria, Belgium and 11 more
- Volunteers
- 476 people
- Sponsor
- Gilead Sciences
HIV Infections
A Study of Enfuvirtide (Fuzeon) in Participants With Advanced Human Immunodeficiency Virus (HIV) Infection
This study assessed the safety and tolerability of enfuvirtide in participants with advanced HIV genotype 1 (HIV-1) disease. Eligible participants who failed treatment with regimens containing at least one product from each…
- Trial name
- NCT02582983
- Testing
- Enfuvirtide
- Where
- 5 sites in Thailand
- Volunteers
- 23 people
- Sponsor
- Hoffmann-La Roche
HIV Infections
A Comparison of Two Dose Levels of Indinavir Combined With Two Nucleoside Analogue Reverse Transcriptase Inhibitors (NRTIs) in HIV-Infected Patients
The purpose of this study is to determine if two dose levels of indinavir combined with two nucleoside analogue reverse transcriptase inhibitors (NRTIs) have the same effect on plasma viral load (level of HIV in the blood).
- Trial name
- NCT00002406
- Testing
- Indinavir sulfate
- Where
- 29 sites in United States
- Volunteers
- 350 people
- Sponsor
- Merck Sharp & Dohme LLC
HIV-1
An Open-label Trial With TMC125 in Patients Who Have Virologically Failed in a DUET Trial (TMC125-C206 or TMC125-C216).
The purpose of this trial is to evaluate the long-term safety and tolerability of TMC125 200 mg twice daily as part of an antiretroviral therapy including TMC114/rtv and an investigator selected optimized background in HIV-1…
- Trial name
- NCT00359021
- Testing
- TMC125
- Where
- 72 sites in United States, Argentina and 12 more
- Volunteers
- 503 people
- Sponsor
- Tibotec Pharmaceuticals, Ireland
HIV, HIV Infections
Study to Evaluate the Safety and Efficacy of E/C/F/TAF (Genvoya®) Versus E/C/F/TDF (Stribild®) in HIV-1 Positive, Antiretroviral Treatment-Naive Adults
The primary objective of this study is to evaluate the efficacy of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) fixed-dose combination (FDC) versus elvitegravir/cobicistat/emtricitabine/tenofovir…
- Trial name
- NCT01780506
- Testing
- E/C/F/TAF, E/C/F/TDF
- Where
- 117 sites in United States, Australia and 10 more
- Volunteers
- 872 people
- Sponsor
- Gilead Sciences
HIV Infections
T-20 in HIV Patients With Prior Drug Treatment and/or Resistance to Each of the Three Classes of Anti-HIV Drugs
The purpose of this study is to show if a dose of T-20 added to an anti-HIV combination (chosen specifically for each patient) lowers viral load by at least a certain level after 24 weeks as compared to an anti-HIV combination…
- Trial name
- NCT00021554
- Testing
- Enfuvirtide
- Where
- 37 sites in Australia, Belgium and 7 more
- Volunteers
- 525 people
- Sponsor
- Hoffmann-La Roche
HIV Infections
Tenofovir DF (Disoproxil Fumarate) in Combination With Emtricitabine in HIV-1 Patients
The purpose of this study is to provide long-term clinical safety and efficacy data for tenofovir disoproxil fumarate and emtricitabine in HIV-infected patients experiencing various degrees of renal impairment.
- Trial name
- NCT00106379
- Testing
- Truvada (tenofovir DF + emtricitabine), Emtriva (emtricitabine), Viread (tenofovir DF)
- Where
- 4 sites in United States
- Volunteers
- 52 people
- Sponsor
- Gilead Sciences
HIV-1
An Efficacy and Safety Study of Autologous Cluster of Differentiation 34 (CD34+) Hematopoietic Progenitor Cells Transduced With Placebo or an Anti- Human Immunodeficiency Virus Type 1 (HIV-1) Ribozyme (OZ1) in Participants With HIV-1 Infection
The purpose of this study is to determine the safety and efficacy of administration of a cell-delivered ribozyme gene transfer product to participants with chronic (lasting a long time) Human Immunodeficiency Virus Type 1 (HIV-1)…
- Trial name
- NCT00074997
- Testing
- OZ1, CD34+ cells
- Where
- Australia
- Volunteers
- 1 people
- Sponsor
- Janssen-Cilag Pty Ltd
HIV Infections
The Safety and Effectiveness of Didanosine Plus Stavudine Plus Delavirdine Mesylate Plus MKC-442 in HIV-Infected Patients Who Have Not Had Success With Protease Inhibitors
The purpose of this study is to see if it is safe and effective to give MKC-442, didanosine (ddI), stavudine (d4T), and delavirdine (DLV) to HIV-positive patients.
- Trial name
- NCT00002420
- Testing
- Emivirine, Hydroxyurea, Delavirdine mesylate
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Bristol-Myers Squibb
Anti-Retroviral Agents, HIV-1
TMC125-C203: Phase II Randomized (Patients Are Assigned Different Treatments Based on Chance), Placebo Controlled Dose Escalating Trial of TMC125 in HIV-1 Infected Patients
The purpose of this randomized (patients are assigned different treatments based on chance), placebo-controlled, dose-escalating trial is to evaluate the safety, tolerability and efficacy of different doses of TMC125 twice daily…
- Trial name
- NCT00412646
- Testing
- TMC125
- Volunteers
- 260 people
- Sponsor
- Tibotec Pharmaceuticals, Ireland
HIV Infections
Pharmacokinetic Interaction Between Nevirapine and Saquinavir-sgc in HIV-1 Infected Patients
The objectives of this study are to determine the effects of nevirapine on the steady-state pharmacokinetics of saquinavir-sgc and to determine the effects of saquinavir-sgc on the steady-state pharmacokinetics of nevirapine.
- Trial name
- NCT02184286
- Testing
- Nevirapine, Saquinavir-sgc
- Volunteers
- 5 people
- Sponsor
- Boehringer Ingelheim